Editas Medicine vs Metagenomi Therapeutics
EDIT and MGX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EDIT and MGX compare
Editas Medicine is the larger company, worth 13 times as much as Metagenomi Therapeutics ($366M against $28.6M).
Metagenomi Therapeutics scores higher on the StockData Score (6 against 3 for Editas Medicine), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EDIT | MGX |
|---|---|---|
| Size and price | ||
| Market cap | $366M | $28.6M |
| Share price | $2.38 | $0.756 |
| Change, 1 year | −5.6% | −64.8% |
| Change, 5 years | −93.3% | – |
| Beta (5Y) | 2.19 | 1.32 |
| Employees | 87 | 119 |
| StockData Score | ||
| Total score | 3 | 6 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 1 (better) | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 7.3× | – |
| P/B | 4.3× | 0.3× (better) |
| FCF yield | −30.2% (better) | −292% |
| Fair value | $1.62 | – |
| Margin of safety | −47.2% | – |
| Growth | ||
| Revenue growth (TTM) | 7.4% | – |
| Revenue growth, 5Y average | −14.9% | – |
| Profitability | ||
| Operating margin | −152% | – |
| Net margin | −145% | – |
| FCF margin | −222% | – |
| Return on equity | −147% | −69.4% (better) |
| Financial health | ||
| Debt / equity | 0.67 (better) | 0.00 |
| Interest coverage | −10.6× | – |
| Current ratio | 2.82 | 3.43 (better) |
| Altman Z-score | −9.39 | −4.63 (better) |
| Piotroski F-score | 1 | 2 (better) |
| Dividends and buybacks | ||
| Buyback yield | −36.6% | – |
| Shareholder yield | −36.6% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 78.3% | 16.6% |
| Held by insiders | 0.45% | 10.4% |
| Insider net buying, 12 months | −$107K | −$9.7K (better) |
| Short interest, % of float | 25.3% | 3.9% |
Go deeper
- EDIT stock overview
- EDIT income statement
- EDIT valuation and score
- MGX stock overview
- MGX income statement
- MGX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.